- Home
- VTGN vs ASMB Comparison
VTGN vs ASMB Comparison
Compare VTGN & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- ASMB
- Stock Information
- Founded
- VTGN 1998
- ASMB 2005
- Country
- VTGN United States
- ASMB United States
- Employees
- VTGN N/A
- ASMB N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- VTGN Health Care
- ASMB Health Care
- Exchange
- VTGN Nasdaq
- ASMB Nasdaq
- Market Cap
- VTGN 81.3M
- ASMB 93.7M
- IPO Year
- VTGN N/A
- ASMB 2010
- Fundamental
- Price
- VTGN $2.92
- ASMB $14.49
- Analyst Decision
- VTGN
- ASMB Buy
- Analyst Count
- VTGN 0
- ASMB 2
- Target Price
- VTGN N/A
- ASMB $35.00
- AVG Volume (30 Days)
- VTGN 401.9K
- ASMB 38.9K
- Earning Date
- VTGN 02-11-2025
- ASMB 11-07-2024
- Dividend Yield
- VTGN N/A
- ASMB N/A
- EPS Growth
- VTGN N/A
- ASMB N/A
- EPS
- VTGN N/A
- ASMB N/A
- Revenue
- VTGN $876,000.00
- ASMB $28,326,000.00
- Revenue This Year
- VTGN N/A
- ASMB $282.16
- Revenue Next Year
- VTGN N/A
- ASMB N/A
- P/E Ratio
- VTGN N/A
- ASMB N/A
- Revenue Growth
- VTGN 8.08
- ASMB N/A
- 52 Week Low
- VTGN $2.22
- ASMB $9.48
- 52 Week High
- VTGN $5.74
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- VTGN 53.24
- ASMB 40.72
- Support Level
- VTGN $2.40
- ASMB $14.17
- Resistance Level
- VTGN $3.40
- ASMB $15.73
- Average True Range (ATR)
- VTGN 0.21
- ASMB 1.02
- MACD
- VTGN -0.00
- ASMB -0.21
- Stochastic Oscillator
- VTGN 47.83
- ASMB 8.72
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.